Metreleptin Ups Resting-State Connectivity in Lipodystrophy

This article originally appeared here.
Share this content:
Metreleptin Ups Resting-State Connectivity in Lipodystrophy
Metreleptin Ups Resting-State Connectivity in Lipodystrophy

WEDNESDAY, May 11, 2016 (HealthDay News) -- For patients with lipodystrophy (LD), resting-state connectivity is significantly increased in three brain areas with metreleptin treatment, with decreased hunger feelings and diminished incentive value of food, according to a study published online May 10 in Diabetes.

Haiko Schlögl, M.D., from the University Hospital Leipzig in Germany, and colleagues performed resting-state functional magnetic resonance imaging scans and extensive behavioral testing during the first 52 weeks of metreleptin treatment in nine patients with LD.

The researchers found that over the course of metreleptin treatment, resting-state connectivity significantly increased in three brain areas: hypothalamus, insula/superior temporal gyrus, and medial prefrontal cortex. During metreleptin therapy, behavioral tests showed that there were significant decreases in perceived hunger, importance of eating, eating frequencies, and liking ratings of food pictures.

"Taken together, leptin substitution was accompanied by long-term changes of hedonic and homeostatic central nervous networks regulating eating behavior, as well as decreased hunger feelings and diminished incentive value of food," the authors write. "It needs to be assessed in future studies whether metreleptin treatment in LD restores physiological processes important for the development of satiety."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »